Serotonin–dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders

Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

2006 • 4,724 citations

Dopamine Receptors: From Structure to Function

1998 • 3,489 citations

THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE

1965 • 3,421 citations

A review of central 5-HT receptors and their function

1999 • 3,121 citations

Psychopharmacology: The Fourth Generation of Progress

1995 • 2,920 citations

The Mesolimbic Dopamine Reward Circuit in Depression

2006 • 1,931 citations

An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat

1978 • 1,887 citations

Molecular, pharmacological and functional diversity of 5-HT receptors

2002 • 1,822 citations

New approaches to antidepressant drug discovery: beyond monoamines

2006 • 1,530 citations

The Role of Dopamine in the Pathophysiology of Depression

2007 • 1,159 citations

Norepinephrine in Depressive Reactions

1965 • 1,127 citations

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

2004 • 1,111 citations

Neurotransmitter Transporters: Recent Progress

1993 • 1,089 citations

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

2003 • 1,008 citations

Medication Augmentation after the Failure of SSRIs for Depression

2006 • 986 citations

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

2003 • 900 citations

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

1998 • 875 citations

Serotonin receptors : their key role in drugs to treat schizophrenia

2003 • 759 citations

H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs

2003 • 758 citations

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

1998 • 719 citations

Clinical and Theoretical Implications of 5-HT₂ and D₂ Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia

1999 • 706 citations

INTENSIFICATION OF THE CENTRAL SEROTONINERGIC PROCESSES AS A POSSIBLE DETERMINANT OF THE THYMOLEPTIC EFFECT

1969 • 705 citations

The Role of Serotonin in Antipsychotic Drug Action

1999 • 672 citations

Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites.

1997 • 635 citations

Half a century of antipsychotics and still a central role for dopamine D2 receptors

2003 • 620 citations

Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness

2006 • 593 citations

Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.

1993 • 588 citations

Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

2006 • 586 citations

Is there a role for 5-HT1A agonists in the treatment of depression?

2003 • 519 citations

Molecular Diversity of the Dopamine Receptors

1993 • 506 citations

From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters

1993 • 461 citations

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

1999 • 427 citations

Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

1999 • 407 citations

Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence.

1994 • 375 citations

Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons

1987 • 374 citations

Antipsychotic drug-induced weight gain mediated by histamine H₁receptor-linked activation of hypothalamic AMP-kinase

2007 • 374 citations

LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake

2007 • 336 citations

Bupropion: pharmacology and therapeutic applications

2006 • 331 citations

Comparison of Amphetamine Psychosis and Schizophrenia

1965 • 328 citations

Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression

2000 • 318 citations

Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system

1997 • 317 citations

Neurotransmitter transporters: molecular function of important drug targets

2006 • 310 citations

Clinical Pharmacology of MAO Inhibitors: Safety and Future

2003 • 308 citations

Effects of Newer Antipsychotics on Extrapyramidal Function

2002 • 304 citations

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride

2002 • 299 citations

Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents

2007 • 299 citations

5-ht6 Receptors

2004 • 296 citations

Targeting the dopamine D₂receptor in schizophrenia

2006 • 292 citations

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

2000 • 290 citations

Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.

2001 • 288 citations

Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study

2007 • 281 citations

Localization and Dynamic Regulation of Biogenic Amine Transporters in the Mammalian Central Nervous System

1998 • 276 citations

The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain

1995 • 272 citations

Brain Serotonin Transporter Binding Potential Measured With Carbon11–Labeled DASB Positron Emission Tomography

2004 • 269 citations

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1995 • 268 citations

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder

2007 • 254 citations

Differential Effects of Aripiprazole on D₂, 5-HT₂, and 5-HT_1AReceptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study

2007 • 234 citations

Neurotransmitter transporters and their impact on the development of psychopharmacology

2006 • 233 citations

Augmentation of Antidepressants With Atypical Antipsychotic Medications for Treatment-Resistant Major Depressive Disorder

2007 • 231 citations

p38 MAPK Activation Elevates Serotonin Transport Activity via a Trafficking-independent, Protein Phosphatase 2A-dependent Process

2005 • 223 citations

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models

2006 • 223 citations

Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review

2006 • 213 citations

The role of 5-HT2A receptors in antipsychotic activity

1995 • 209 citations

GPCR functional selectivity has therapeutic impact

2007 • 204 citations

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

2007 • 203 citations

Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment

2001 • 200 citations

Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models

2005 • 195 citations

The pipeline and future of drug development in schizophrenia

2007 • 185 citations

An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine.

1998 • 183 citations

Differentiating antidepressants of the future: Efficacy and safety

2006 • 175 citations

Invited review: the evolution of antidepressant mechanisms

2004 • 175 citations

Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens

2001 • 174 citations

Tyr-95 and Ile-172 in Transmembrane Segments 1 and 3 of Human Serotonin Transporters Interact to Establish High Affinity Recognition of Antidepressants

2005 • 172 citations

The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats

2002 • 160 citations

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

1999 • 157 citations

Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade

2004 • 156 citations

Positron Emission Tomography Studies on D2 and 5-HT2 Receptor Binding in Risperidone-Treated Schizophrenic Patients

1995 • 156 citations

5-HT 6 receptor antagonists enhance retention of a water maze task in the rat

2001 • 154 citations

Catecholamine hypothesis of affective disorders

1969 • 153 citations

Partial dopamine agonists in the treatment of psychosis

2002 • 147 citations

Glutamate and monoamine transporters: new visions of form and function

2007 • 145 citations

The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585

2002 • 144 citations

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

2006 • 142 citations

5‐HT₆ receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex

2003 • 142 citations

Beyond the monoamine hypothesis: mechanisms, molecules and methods

2002 • 138 citations

Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants

2005 • 126 citations

Binding of Antipsychotic Drugs to Cortical 5-HT_2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients

1998 • 125 citations

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: A meta-analysis of the randomized controlled trials

2006 • 124 citations

The Pharmacology of Citalopram Enantiomers: The Antagonism by R‐Citalopram on the Effect of S‐Citalopram*

2006 • 122 citations

5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats

1996 • 120 citations

Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nuclei

2004 • 119 citations

The Selective 5-HT2A Receptor Antagonist M100907 Enhances Antidepressant-Like Behavioral Effects of the SSRI Fluoxetine

2005 • 117 citations

Augmentation strategies for treatment-resistant depression: a literature review

2007 • 110 citations

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

2007 • 106 citations

Triple uptake inhibitors: therapeutic potential in depression and beyond

2007 • 106 citations

Antipsychotic-Like vs Cataleptogenic Actions in Mice of Novel Antipsychotics Having D2 Antagonist and 5-HT1A Agonist Properties

2005 • 106 citations

Pindolol Augmentation of Antidepressant Response

2006 • 105 citations

An Open Trial of Buspirone Added to Neuroleptics in Schizophrenic Patients

1991 • 97 citations

Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat

2005 • 94 citations

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [ 123 I]epidepride single photon emission tomography (SPET) study

2000 • 88 citations

5‐HT₆ receptor binding sites in schizophrenia and following antipsychotic drug administration: Autoradiographic studies with [¹²⁵I]SB‐258585

2002 • 85 citations

Augmentation of SSRI Effects on Serotonin by 5-HT2C Antagonists: Mechanistic Studies

2007 • 82 citations

Antidepressant-lnduced Liver Injury

2007 • 82 citations

Behavioral Studies of Hallucinogenic Drugs in Animals: Implications for Schizophrenia Research

1998 • 81 citations

The CRF1 Receptor, a Novel Target for the Treatment of Depression, Anxiety, and Stress-Related Disorders

2007 • 78 citations

R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.

1999 • 76 citations

Serotonin transporters: Implications for antidepressant drug development

2005 • 71 citations

Aripiprazole acts as a selective dopamine D₂receptor partial agonist

2007 • 71 citations

A preclinical and clinical rationale for quetiapine in mood syndromes

2007 • 67 citations

Cardiovascular risks of atypical antipsychotic drug treatment

2007 • 67 citations

The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys

2000 • 67 citations

Targeting of serotonin 1a receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain

2001 • 61 citations

Evidence that dopamine mechanisms in the nucleus accumbens are selectively involved in the effect of desipramine in the forced swimming test

1987 • 58 citations

F15063, a compound with D₂/D₃ antagonist, 5‐HT_1A agonist and D₄ partial agonist properties: (III) Activity in models of cognition and negative symptoms

2007 • 56 citations

5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus

2007 • 54 citations

Neurokinin 1 receptor antagonists--current prospects.

2007 • 54 citations

Repeated treatment with imipramine and amitriptyline reduced the immobility of rats in the swimming test by enhancing dopamine mechanisms in the nucleus accumbens

1988 • 53 citations

Antidepressant-like activity of selective serotonin reuptake inhibitors combined with a NK1 receptor antagonist in the mouse forced swimming test

2006 • 53 citations

PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram

2007 • 51 citations

Studies towards the identification of a new generation of atypical antipsychotic agents

2006 • 51 citations

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050

2006 • 49 citations

The developing use of heterozygous mutant mouse models in brain monoamine transporter research

2007 • 49 citations

The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects

2005 • 47 citations

Pharmacological approaches to the treatment of residual symptoms

2006 • 46 citations

Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex

2007 • 43 citations

Therapeutic Potential of 5-HT2C Receptor Antagonists in the Treatment of Anxiety Disorders

2003 • 42 citations

Differential Effects of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxyl]-5-pyridyl]carbamoyl]-6-trifluoromethylindone (SB 243213) on 5-Hydroxytryptamine_2C Receptor-Mediated Responses

2006 • 41 citations

F15063, a potential antipsychotic with D₂/D₃ antagonist, 5‐HT_1A agonist and D₄ partial agonist properties: (I) in vitro receptor affinity and efficacy profile

2007 • 40 citations

Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.

1996 • 39 citations

Pharmacological Profile of Antipsychotics at Monoamine Receptors: Atypicality Beyond 5-HT2A Receptor Blockade

2006 • 33 citations

Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.

2007 • 32 citations

A model to explain the therapeutic effects of serotonin reuptake inhibitors: the role of 5-HT2 receptors.

2006 • 32 citations

Blockade of tachykinin NK1 receptors attenuates stress‐induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex

2006 • 32 citations

Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia

2007 • 28 citations

Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters

2005 • 26 citations

Creating more effective antidepressants: clues from the clinic

2006 • 24 citations

5‐HT_2C receptor antagonists: Potential in schizophrenia

2001 • 23 citations

Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.

2007 • 23 citations

Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.

2007 • 14 citations

Structure–activity relationships of substituted N-benzyl piperidines in the GBR series: Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(2-trifluoromethylbenzyl)piperidine, an allosteric modulator of the serotonin transporter

2006 • 14 citations

Augmentation strategies to increase antidepressant efficacy.

2007 • 13 citations

Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 – 2006

2007 • 11 citations

RNA interference for studying the molecular basis of neuropsychiatric disorders.

2007 • 9 citations

Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?

2005 • 7 citations